iSpecimen Announces 1-for-6 Reverse Stock Split
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
iSpecimen (ISPC) will implement a 1-for-6 reverse stock split of its common stock, including treasury shares, on November 23, 2026. The split takes effect at 4:30 p.m. Eastern Time, and split-adjusted trading begins November 24, 2026 at the Nasdaq Capital Market open under the same ticker. Outstanding common shares will fall from 5,789,013 to 964,836.
Shareholders authorized the split on October 30, 2026, and the board set the ratio on November 11, 2026. iSpecimen says the split is intended to raise the per-share trading price to attract certain investors and maintain compliance with Nasdaq’s minimum bid price requirement.
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.1-for-6 reverse stock split is intended in part to maintain compliance with Nasdaq’s minimum bid price requirement
News Explained
When the announced split takes effect, it also proportionately adjusts outstanding options’ and warrants’ exercise prices and share counts, the shares issuable upon restricted stock unit vesting, and shares reserved under incentive plans, with any resulting fractional common share rounded up to a whole share at the participant level.
Key Figures
- Reverse split ratio
- 1-for-6
- Approved by the Board on November 11, 2026
- Effective date
- November 23, 2026 at 4:30 p.m. Eastern Time
- Reverse stock split effective time
- Split-adjusted trading begins
- November 24, 2026
- When the common stock is scheduled to begin split-adjusted trading
- Shares issued and outstanding
- 5,789,013 to 964,836 shares
- Immediately before and following the reverse stock split
Previous Stock split Reports
-
A prior 1-for-40 reverse split was followed by a 19.61% 24-hour decline.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
reverse stock split financial
par value financial
cusip number financial
restricted stock units financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Woburn, Massachusetts--(Newsfile Corp. - November 19, 2026) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today that it will effect a reverse stock split of its issued and outstanding shares of common stock, par value
The reverse stock split will become effective at 4:30 p.m. Eastern Time on November 23, 2026, and the Company's common stock will begin trading on a split-adjusted basis when the market opens on November 24, 2026. The Company's common stock will continue to trade on the Nasdaq Capital Market ("Nasdaq") under the symbol "ISPC." The new CUSIP number for the Company's common stock following the reverse stock split will be 45032V405. Immediately prior to the effectiveness of the reverse stock split, the Company had 5,789,013 shares of common stock issued and outstanding, which will be reduced to 964,836 shares following the reverse stock split.
At the Company's special meeting of stockholders held on October 30, 2026, the stockholders approved a proposal to amend the Company's Fifth Amended and Restated Certificate of Incorporation to effect a reverse stock split, with the final ratio to be determined by the Board of Directors (the "Board"). On November 11, 2026, the Board approved a 1-for-6 reverse stock split.
When the reverse stock split becomes effective, every 6 shares of the Company's issued and outstanding common stock, as well as all shares held by the Company in treasury, will automatically be combined into one share of common stock, without any change in the par value per share. In addition, (i) a proportionate adjustment will be made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock options and warrants to purchase shares of common stock, (ii) a proportionate adjustment will also be made in the number of shares of common stock issuable upon the vesting of restricted stock units, and (iii) the number of shares reserved for issuance pursuant to the Company's stock incentive plans will also be reduced proportionately. Any fraction of a share of common stock that would be created as a result of the reverse stock split will be rounded up to the nearest whole share at the participant level.
The reverse stock split is intended to increase the per share trading price of the Company's common stock to better attract certain institutional and other investors [and to maintain compliance with the minimum bid price requirement for continued listing of the Company's common stock on Nasdaq].
Broadridge Corporate Issuer Solutions, LLC ("Broadridge"), the Company's transfer agent, will act as the exchange agent for the reverse stock split. Registered stockholders holding pre-split shares of the common stock electronically in book-entry form are not required to take any action to receive post-split shares. Stockholders of record holding certificated shares will receive information from Broadridge about the process for exchanging their pre-split shares for post-split shares. Stockholders who hold their shares in brokerage accounts or in "street name" are not required to take any action in connection with the reverse stock split.
About iSpecimen
iSpecimen (NASDAQ: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," "believe," "estimate," "continue" or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information.
Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk factors contained in the Company's filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company's forward-looking statements occurs, the Company's business, financial condition and operating results may vary materially from those expressed in the Company's forward-looking statements.
Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/324757
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.